Categories
Tags
Authors: Hashim HA, Maulood MF, rasheed AM, Fatak DF, Kabah KK. doi: https://doi.org/10.1101/2020.10.26.20219345 Abstract Objectives COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try repurposed old drugs on COVID-19. Methods Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 [...]
Categories: I-CARE Early Covid
Tags:
Authors: Goren A, Wambler CG, Herrera S, McCoy J, Gioia F PMID: 32977363 PMCID: PMC7536996 DOI: 10.1111/jdv.16953 Abstract The COVID-19 pandemic has disproportionally affected men.1 Men infected with SARS-CoV-2 are more than twice as likely to be admitted to the intensive care unit (ICU).2 This disparity in ICU admissions suggests the important role of androgens [...]
Categories: I-CARE Early Covid
Tags:
Authors: Valizadeh H, Danshina S, Gencer MZ, Ammari A, Sadeghi A, Aslani S. PMID: PMC7574843 DOI: 10.1016/j.intimp.2020.107088 Abstract Background: As an ongoing worldwide health issue, Coronavirus disease 2019 (COVID-19) has been causing serious complications, including pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. However, there is no decisive treatment approach available for this disorder, [...]
Categories: I-CARE Early Covid, I-PREVENT, I-RECOVER Post-Vaccine
Authors: Yeramaneni S, Doshi P, Sands K, Cooper M, Kurbegov D, Fromell G PMID: 33058865 PMCID: PMC7550093 doi: 10.1053/j.gastro.2020.10.011 Abstract Previous reports have found that in-hospital famotidine use in coronavirus disease 2019 (COVID-19) patients was associated with reduced risk of death or intubation.1 , 2 In 1 of these studies the authors proposed that famotidine [...]
Categories: I-CARE Early Covid
Tags: COVID-19, Famotidine
Authors: Mather JF, Seip RL, McKay RG PMID: 32852338 PMCID: PMC7473796 DOI: 10.14309/ajg.0000000000000832 Abstract Introduction: To compare outcomes in patients hospitalized with coronavirus (COVID-19) receiving famotidine therapy with those not receiving famotidine. Methods: Retrospective, propensity-matched observational study of consecutive COVID-19-positive patients between February 24, 2020, and May 13, 2020. Results: Of 878 patients in the [...]
Categories: I-CARE Early Covid
Tags: COVID-19, Famotidine
Authors: Chamie J Abstract In these eight Peruvian State analyses, Ivermectin distributions preceded sound reductions in excess deaths and case fatality rate (CFR). The variation in the number of detected cases nor the vulnerable population decrease can explain this reduction. Other possible explanations, such as cross-immunity with dengue, or mere causality, have been discarded due [...]
Categories: I-CARE Early Covid, MATH+
Tags: COVID-19, ivermectin
Authors: Derosa G, Maffioli P, D'Angelo A, Di Pierro F. doi: https://doi.org/10.1002/ptr.6887 Abstract Several months ago, an outbreak of pneumonia of unknown aetiology was detected in Wuhan City (China) and the aetiological agent of the atypical pneumonia was isolated by the Chinese authorities as novel coronavirus (2019-nCoV or SARS-CoV-2). The WHO announced this new disease [...]
Categories: I-CARE Early Covid, I-PREVENT
Tags:
Authors: Cadegiani FA, Goren A, Wambier CG, McCoy J doi: https://doi.org/10.1101/2020.10.05.20206870 Abstract Background While COVID-19 remains largely unclear and mortality continues to raise, early effective approaches prior to complications lack, as well as researches for characterization and therapeutical potential options in actual early COVID-19. Although females seem to be less affected than females, hyperandrogenic (HA) [...]
Categories: I-CARE Early Covid
Tags:
Authors: Lehrer S, Rheinstein PH PMID: 32871846 PMCID: PMC7652439 DOI: 10.21873/invivo.12134 Abstract Background/aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking [...]
Categories: I-CARE Early Covid, I-RECOVER Post-Vaccine, MATH+
Tags: ACE2 protein, ivermectin, SARS-CoV-2
Authors: Sethia R, Prasad M, Mahapatra SJ, Nischal N, Soneja M doi: https://doi.org/10.1101/2020.09.28.20203463 Abstract Background Coronavirus Disease 2019 (COVID-19) pandemic continues unabated in many parts of the world. In the absence of any definite antiviral therapy except some benefit of remdesivir, there is an ongoing search for effective therapy. Famotidine has been shown to reduce [...]
Categories: I-CARE Early Covid
Tags: COVID-19, Famotidine